Last reviewed · How we verify
Secondary hyperparathyroidism
Approved treatments
- Upasita · SANWA KAGAKU KENKYUSHO Co., Ltd.
- Orkedia · Kyowa Hakko Kirin Co., Ltd.
- Parsabiv · Kai Pharms Inc
Etelcalcetide enhances calcium-sensing receptor activation, reducing PTH secretion.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Secondary hyperparathyroidism patent landscape — cliff calendar, originator estates, attackable patents
- Secondary hyperparathyroidism treatment landscape brief
- Secondary hyperparathyroidism treatment updates RSS
Frequently asked questions about Secondary hyperparathyroidism
What drugs treat Secondary hyperparathyroidism?
Tracked treatments include Upasita, Orkedia, Parsabiv.
What is the treatment for Secondary hyperparathyroidism?
Standard treatment for Secondary hyperparathyroidism includes Upasita, Orkedia, Parsabiv. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Secondary hyperparathyroidism patent cliff · Secondary hyperparathyroidism CI report
- Treatment: Upasita · SANWA KAGAKU KENKYUSHO Co., Ltd.
- Treatment: Orkedia · Kyowa Hakko Kirin Co., Ltd.
- Treatment: Parsabiv · Kai Pharms Inc
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing